Back to Authors

Cruz, Anthony

0009-0003-3799-2103

Mayo Clinic

National Institutes of Health

Citations 2

Cutting Edge: Rac GTPases Sensitize Activated T Cells to Die via Fas
Ramaswamy, Madhu , Dumont, Céline , Cruz, Anthony , Muppidi, Jagan , Gomez, Timothy S., Billadeau, Daniel D. , Tybulewicz, Victor L. J. , Siegel, Richard M.

The Journal of Immunology | April 18, 2014 | Volume: 179 | Issue: 10 | Pages: 6384-6388

10.4049/jimmunol.179.10.6384 Get It

Abstract In activated CD4+ T cells, TCR restimulation triggers apoptosis that depends on interactions between the death receptor Fas and its ligand, FasL. This process, termed restimulation-induced cell death (RICD), is a mechanism of peripheral immune tolerance. TCR signaling sensitizes activated T cells to Fas-mediated apoptosis, but what pathways mediate this process are not known. In this study we identify the Rho GTPases Rac1 and Rac2 as essential components in restimulation-induced cell death. RNA interference-mediated knockdown of Rac GTPases greatly reduced Fas-dependent, TCR-induced apoptosis. The ability of Rac1 to sensitize T cells to Fas-induced apoptosis correlated with Rac-mediated cytoskeletal reorganization, dephosphorylation of the ERM (ezrin/radixin/moesin) family of cytoskeletal linker proteins, and the translocation of Fas to lipid raft microdomains. In primary activated CD4+ T cells, Rac1 and Rac2 were independently required for maximal TCR-induced apoptosis. Activating Rac signaling may be a novel way to sensitize chronically stimulated lymphocytes to Fas-induced apoptosis, an important goal in the treatment of autoimmune diseases.
The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function
Lee, John J. , Rauter, Ingrid, Garibyan, Lilit , Özcan, Esra , Sannikova, Tatyana , Dillon, Stacey R. , Cruz, Anthony , Bram, Richard J. , Jabara, Haifa H., Geha, Raif S. , Siegel, Richard M.

Blood | July 16, 2009 | Volume: 114 | Issue: 11 | Pages: 2254-2262

10.1182/blood-2008-11-189720 Get It

AbstractTNFRSF13B, which encodes TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor), is mutated in 10% of patients with common variable immune deficiency (CVID). One of the 2 most common TACI mutations in CVID, A181E, introduces a negative charge into the transmembrane domain. To define the consequence of the A181E mutation on TACI function, we studied the effect of its murine equivalent, mTACI A144E, on TACI signaling in transfected cells and on TACI function in transgenic mice. The mTACI A144E mutant, like its human TACI A181E counterpart, was expressed on the surface of 293T transfectants and was able to bind ligand, but exhibited impaired constitutive and ligand-induced NFκB signaling. In addition, constitutive and ligand-induced clustering of the intracellular domain was deficient for A144E as measured by fluorescence resonance energy transfer. Transgenic mice expressing the A144E mutant on TACI−/− background had low serum IgA levels and significantly impaired antibody responses to the type II T-independent antigen TNP-Ficoll. B cells from A144E transgenic mice were impaired in their capacity to proliferate and secrete IgG1 and IgA in response to TACI ligation. These results suggest that mTACI A144E mutation and its human counterpart, A181E, disrupt TACI signaling and impair TACI-dependent B-cell functions.